0001562180-24-005608.txt : 20240703
0001562180-24-005608.hdr.sgml : 20240703
20240703173421
ACCESSION NUMBER: 0001562180-24-005608
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20240701
FILED AS OF DATE: 20240703
DATE AS OF CHANGE: 20240703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Perry Andrew
CENTRAL INDEX KEY: 0001877793
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38096
FILM NUMBER: 241101059
MAIL ADDRESS:
STREET 1: C/O G1 THERAPEUTICS, INC.
STREET 2: 700 PARK OFFICES DRIVE, SUITE 200
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: G1 Therapeutics, Inc.
CENTRAL INDEX KEY: 0001560241
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 263648180
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 700 PARK OFFICES DRIVE
STREET 2: SUITE 200
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
BUSINESS PHONE: 919-213-9835
MAIL ADDRESS:
STREET 1: 700 PARK OFFICES DRIVE
STREET 2: SUITE 200
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
FORMER COMPANY:
FORMER CONFORMED NAME: G-Zero Therapeutics, Inc.
DATE OF NAME CHANGE: 20121012
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-07-01
false
0001560241
G1 Therapeutics, Inc.
GTHX
0001877793
Perry Andrew
700 PARK OFFICES DRIVE, SUITE 200
RESEARCH TRIANGLE PARK
NC
27709
false
true
false
false
Chief Commercial Officer
false
Common Stock
2024-07-01
4
A
false
35000.00
0.00
A
113951.00
D
Represents a restricted stock unit ("RSU") award that vests 50% on July 1, 2025 and 50% on July 1, 2026, subject to the Reporting Person's continued service through each applicable vesting date.
Each RSU represents a contingent right to receive one share of Issuer common stock.
Represents (i) 12,806 shares of common stock; (ii) 3,000 RSUs from award granted on January 3, 2022; (iii) 12,075 RSUs from award granted on January 3, 2023; (iv) 17,500 RSUs from award granted on May 10, 2023; (v) 33,570 RSUs from award granted on January 3, 2024; and (vi) 35,000 RSUs from award granted on July 1, 2024.
/s / Monica Roberts Thomas, attorney-in-fact
2024-07-03
EX-24
2
aperrypoa.txt
POA2
POWER OF ATTORNEY
Know all by these present, that the undersigned hereby
constitutes and appoints each of Monica Roberts Thomas, General
Counsel, of G1 Therapeutics, Inc. (the "Company"), John W.
Umstead V, Chief Financial Officer, Sandi James, Director, Legal, of
the Company, and Jason McCaffrey, Raven Sun, Justin Omalev, Charles
Smith, Tanya Sylla, and Brenda Meyette of Mintz, Levin, Cohn,
Ferris, Glovsky and Popeo, P.C., signing singly, with full power of
substitution, the undersigned's true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, forms and
authentication documents for EDGAR Filing Access;
(2) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to
complete and execute any such forms and authentication
documents;
(3) execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer, director and/or 10%
shareholder of the Company, Forms 3, 4 and 5 in accordance
with Section 16(a) of the Securities Exchange Act of 1934
and the rules thereunder;
(4) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to
complete and execute any such Form 3, 4 or 5 and timely
file such form with the United States Securities and
Exchange Commission and any stock exchange or similar
authority; and
(5) take any other action of any type whatsoever in connection
with the foregoing which, in the opinion of such attorney-
in-fact, may be of benefit to, in the best interests of,
or legally required by the undersigned, it being
understood that the documents executed by such attorney-
in-fact on behalf of the undersigned pursuant to this
Power of Attorney shall be in such form and shall contain
such terms and conditions as such attorney-in-fact may
approve in such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform any and every act and thing
whatsoever requisite, necessary, or proper to be done in the
exercise of any of the rights and powers herein granted, as fully to
all intents and purposes as the undersigned might or could do if
personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or
such attorney-in-fact's substitute or substitutes, shall lawfully do
or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned acknowledges that
the foregoing attorneys-in-fact, in serving in such capacity at the
request of the undersigned, are not assuming, nor is the Company
assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Securities Exchange Act of 1934, as amended.
This Power of Attorney shall remain in full force and effect
until the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the
undersigned in a signed writing delivered to the foregoing attorneys-
in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed on December 4, 2023.
/s/ Andrew Perry
Signature
Andrew Perry
Print Name